HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewington, V. J. Search for Related Content PubMed PubMed Citation Articles by Lewington, V. J.

Bone-Seeking Radionuclides For Therapy

Royal Marsden Hospital, Sutton, England, United Kingdom

Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the treatment of multisite metastatic pain. Evidence supporting the use of ß-particle, electron, and -particle–emitting radiopharmaceuticals is reviewed here. Appropriate patient selection relies on correlating clinical symptoms with focal abnormalities on conventional bone scintigraphy. Time to symptom relief and response duration vary with the physical half-life and dose rate of the radionuclide used, offering the opportunity to tailor radiopharmaceutical choice to individual patient circumstances. Toxicity is limited to temporary myelosuppression, governed by the administered activity and underlying bone marrow reserve. Optimal responses are achieved in patients with a modest skeletal tumor burden, suggesting that targeted therapy should be considered early in the management of bone metastases. The development of reliable dosimetric models will facilitate patient-specific prescribing to deliver enhanced symptom response within acceptable toxicity limits. It is likely that targeted therapy will be most effective in the context of multimodality tumor management. Further research is required to examine the potential of radionuclides in combination with external-beam irradiation, bisphosphonates, or chemotherapy. This approach might allow targeted therapy to progress beyond symptom palliation to early intervention for survival gain.

Key Words: bone pain palliation • metastasis • targeted radionuclide therapy • dosimetry

This article has been cited by other articles:

				K. Ogawa, T. Mukai, D. Asano, H. Kawashima, S. Kinuya, K. Shiba, K. Hashimoto, H. Mori, and H. Saji Therapeutic Effects of a 186Re-Complex-Conjugated Bisphosphonate for the Palliation of Metastatic Bone Pain in an Animal Model J. Nucl. Med., January 1, 2007; 48(1): 122 - 127. [Abstract] [Full Text] [PDF]